In a phase Ib clinical trial involving patients with advanced metastatic melanoma, Andtbacka et al. reported that treatment with the CXCR4 inhibitor mavorixafor for three weeks enhanced the recruitment of CD8+ T cells into melanoma lesions. The gene discussed is CD8A; the disease is melanoma.